Search Results: (30 results)

This study is testing a new targeted drug called daraxonrasib to see if it helps people with metastatic pancreatic cancer live longer or keep their cancer from growing longer than standard chemotherapy alone. Researchers are comparing daraxonrasib by itself or combined with chemotherapy to standard chemotherapy.

This study tests whether COM701 (an anti‑PVRIG immunotherapy) given every 3 weeks as maintenance can delay cancer growth after a good response to platinum chemotherapy. Adults with relapsed platinum‑sensitive ovarian, fallopian tube, or primary peritoneal cancer are randomized 2:1 to COM701 or placebo.

This trial will study the safety, tolerability, and initial effectiveness of MOMA-341, a new type of targeted therapy, alone or in combination with a standard chemotherapy (irinotecan) or together with an immunotherapy to treat people with advanced or metastatic cancers with certain types of mutations.

We are conducting a fully-online research study to learn more about how genes affect your risk of breast cancer. No office visit is required. Participants provide consent online, answer questions online about their health and medical history, and provide DNA via a saliva sample using a pre-paid mailer through the mail. In return for participation, study participants may receive information about their genetic ancestry for free.

The Vanguard Study is looking at how multi-cancer detection (MCD) blood tests could fit into cancer screening.

Randomized controlled trial, seeking to enroll Black and Latina women ages 18-74 who are at high risk for breast cancer

This registry is collecting cancer-related information from people with triple-negative breast cancer and from people with inherited mutations linked to breast and ovarian cancer, such as an ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, EPCAM, MLH1, MSH2, MSH6, NF1, PALB2, PTEN, RAD51C, RAD51D, STK11, TP53 genetic mutation

This study is for people with prostate cancer that is considered high risk for recurrence. It compares two radiation therapy schedules to see whether a shorter course of treatment works as well as the standard, longer course at preventing the cancer from coming back or spreading.

This is a Phase III, randomized, global, open-label clinical trial to see if a new drug Daraxorasib (RMC-6236) helps prevent pancreatic cancer from returning after surgery and chemotherapy.

The purpose of this study is to understand knowledge and opinions about pancreatic cancer screening, access to and decision-making around screening, and how a blood-based test might influence screening among individuals with inherited (germline) mutations associated with increased pancreatic cancer risk, including APC, ATM, BRCA1, BRCA2, CDKN2A, EPCAM, MLH1, MSH2, MSH6, PALB2, PMS2, STK11, and TP53. 

This is a long-term observational study designed to improve early detection and prevention of ovarian and other gynecologic cancers.

This observational study follows participants over time to better understand the long-term effects of nipple-sparing mastectomy.

This study is testing a personalized cancer vaccine designed using proteins (called neoantigens) taken directly from a person’s tumor.

This study is testing whether taking daraxonrasib, a new oral cancer medicine, after surgery and standard chemotherapy can help people with pancreatic cancer stay cancer-free for longer.

This study is testing two different vaccine-based treatment approaches combined with immunotherapy for people with pancreatic cancer that can be removed with surgery

This clinical trial is testing whether two targeted cancer drugs taken together work better than one drug alone for treating advanced endometrial cancer that has come back or did not respond to prior treatment. To be eligible, the cancer must test positive for a biomarker known as a RAS pathway mutation.

Researchers are conducting a study to better understand how people make important health decisions and how they feel about those decisions over time. The goal of this study is to learn what factors help patients feel confident and satisfied with their health-related decisions, as well as what may lead to regret or uncertainty later on.

This research study is enrolling prostate cancer patients who plan to undergo surgery to have their prostate removed (radical prostatectomy) and whose cancer has one of the listed gene mutations: ATM, BRCA1, BRCA2, CHEK2, PALB2, RAD51B, RAD51C, RAD51D, RAD54L2, BARD1, FANCA or BRIP1.

Research study on how couples’ experience with cancer-related financial challenges affects their health and relationship.

Online survey recruiting participants who reside in the United States, have been diagnosed with cancer, and are 18 years or older.

This study is looking at how well an experimental blood test works for finding cancer earlier in people who have a higher-than-average risk of cancer because of an inherited mutation. Note: This study is only open in Canada. 

This study is testing an experimental vaccine that helps the immune system recognize changes in a protein called KRAS, which is commonly involved in pancreatic cancer. The vaccine is given with an immune-boosting medicine that helps improve the body’s response.

This study is testing whether a new targeted therapy called AZD5335 works better than currently used treatments for people with platinum‑resistant ovarian, fallopian tube, or primary peritoneal cancer.The study is looking at how long people live without their cancer getting worse while taking AZD5335 compared with standard treatments. 

This study is testing whether a type of blood test called a liquid biopsy can find very small amounts of cancer left in the body after treatment—before cancer shows up on scans or causes symptoms.The blood test looks for circulating tumor DNA (ctDNA), tiny pieces of cancer DNA that may be present in the bloodstream. Researchers want to learn how well this test can:

• Detect cancer recurrence early
• Predict outcomes after treatment
• Support future use of blood‑based monitoring instead of—or in addition to—imaging tests

This study is evaluating whether a surgical support mesh called GalaFLEX LITE™ Scaffold can improve outcomes for women undergoing revision breast implant surgery due to complications such as capsular contracture (hardening of scar tissue around the implant).

This trial will study the safety, tolerability, and initial effectiveness of MOMA-313, a new type of targeted therapy, alone or in combination with the PARP inhibitor olaparib to treat people with advanced or metastatic cancers with certain types of mutations.

This study is looking at whether a menstrual cup can be used as a simple, non-invasive way to collect menstrual blood for detection of endometrial (uterine) cancer earlier—especially in people with Lynch syndrome or others at high risk.

This study collects health information and DNA samples such as blood or saliva from participants to help researchers better understand cancer risk and early detection.

Genetic risk screening and genetic testing study for Black/African American adults ages 18 and older in the Houston, Texas area.

This phase II study is testing low-dose tamoxifen, with or without high-dose omega-3 fatty acids, in postmenopausal women who are overweight or obese and at increased risk for breast cancer.